All In Biotech

Drug Trial Radar · NCT06612151

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)

A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Compare the Efficacy and Safety of YL201 Versus Topotecan Hydrochloride in Subjects With Relapsed Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 438 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

438

Planned (sponsor's estimate)

Start

Dec 17, 2024

Primary completion

Dec 1, 2027

Study completion Dec 1, 2030

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).

Conditions

  • Small Cell Lung Cancer

Interventions

  • YL201Drug

    Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle at RP3D dose level.

  • topotecan hydrochloride for injectionDrug

    Topotecan hydrochloride will be administered intravenously per prescribing information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the OS of YL201 versus topotecan hydrochloride in subjects with relapsed SCLC.Time frame: Approximately within 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.